Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last981 to 1,000 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Dietary Supplement/Vitamins vs Placebo for Vitamin C and Vitamin E: Maternal Death | 1 of 4,993 1 of 4,976 | -0.0 points -0.1 to 0.1 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Aspartate Aminotransferase ≥100 U/Liter | 35 of 4,993 48 of 4,976 | -0.3 points -0.6 to 0.1 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level | 7 of 4,993 11 of 4,976 | -0.1 points -0.3 to 0.1 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death | 12 of 4,993 11 of 4,976 | 0.0 points -0.2 to 0.2 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate | 305 of 4,993 285 of 4,976 | 0.4 points -0.5 to 1.3 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure | 10 of 4,993 4 of 4,976 | 0.1 points -0.0 to 0.3 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| VAX-MOM Intervention vs Standard of Care: Rate of Influenza Vaccination | 2,382 of 4,609 2,496 of 5,294 | 4.5 points 2.6 to 6.5 | 9,903 | NCT04444518 Increasing Influenza and Tdap Vaccination of Pregnant Women |
| Dulaglutide vs Placebo: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) | 594 of 4,949 663 of 4,952 | -1.4 points -2.7 to -0.1 | 9,901 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Dulaglutide vs Placebo: Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit | 213 of 4,949 226 of 4,952 | -0.3 points -1.1 to 0.6 | 9,901 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina | 88 of 4,949 77 of 4,952 | 0.2 points -0.3 to 0.7 | 9,901 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to All-cause Mortality | 536 of 4,949 592 of 4,952 | -1.1 points -2.4 to 0.1 | 9,901 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint | 1,099 of 4,949 1,241 of 4,952 | -2.9 points -4.5 to -1.2 | 9,901 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Vitamins vs Placebo: Cesarean Delivery | 1,269 of 4,958 1,224 of 4,940 | 0.8 points -0.9 to 2.5 | 9,898 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Intensive Protocol vs Usual Care Protocol: Mortality | 1,856 of 5,133 1,756 of 4,763 | -0.7 points -2.6 to 1.2 | 9,896 | NCT02933151 Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial) |
| Intensive Protocol vs Usual Care Protocol: deaths from any cause | 1,827 of 5,133 1,732 of 4,763 | -0.8 points -2.7 to 1.1 | 9,896 | NCT02933151 Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial) |
| Vitamins vs Placebo: Placental Abruption | 24 of 4,957 36 of 4,938 | -0.2 points -0.6 to 0.1 | 9,895 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Antepartum Bleeding | 56 of 4,956 46 of 4,937 | 0.2 points -0.2 to 0.6 | 9,893 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Dulaglutide vs Placebo: deaths from any cause | 536 of 4,943 592 of 4,949 | -1.1 points -2.4 to 0.1 | 9,892 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Dulaglutide vs Placebo: serious adverse events | 1,991 of 4,943 2,044 of 4,949 | -1.0 points -3.0 to 0.9 | 9,892 | NCT01394952 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Vitamins vs Placebo: Medically Indicated Delivery Because of Hypertension | 509 of 4,952 473 of 4,934 | 0.7 points -0.5 to 1.9 | 9,886 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=50
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00135707-ac3342e8",
"title": "Dietary Supplement/Vitamins vs Placebo for Vitamin C and Vitamin E: Maternal Death",
"summary": "1 of 4993 against 1 of 4976; risk difference -0.0 points, 95% interval -0.1 to 0.1; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
"record": "/library/comparisons/NCT00135707-ac3342e8",
"nct_id": "NCT00135707",
"kind": "outcome",
"participants": 9969,
"risk_difference": {
"value": -6.842376755109817e-7,
"lower": -0.000951674786951715,
"upper": 0.0009472671832005352
},
"group_1": "1 of 4,993",
"group_2": "1 of 4,976",
"difference": "-0.0 points",
"interval": "-0.1 to 0.1",
"trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
},
{
"id": "NCT00135707-b98f96fd",
"title": "Vitamins vs Placebo: Aspartate Aminotransferase ≥100 U/Liter",
"summary": "35 of 4993 against 48 of 4976; risk difference -0.3 points, 95% interval -0.6 to 0.1; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
"record": "/library/comparisons/NCT00135707-b98f96fd",
"nct_id": "NCT00135707",
"kind": "outcome",
"participants": 9969,
"risk_difference": {
"value": -0.0026364885115689306,
"lower": -0.006323052065825137,
"upper": 0.000968694715300299
},
"group_1": "35 of 4,993",
"group_2": "48 of 4,976",
"difference": "-0.3 points",
"interval": "-0.6 to 0.1",
"trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=51",
"request_id": "DInX_KEaB22k_dI1"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant